<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828477</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0144</org_study_id>
    <nct_id>NCT00828477</nct_id>
  </id_info>
  <brief_title>Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)</brief_title>
  <official_title>Evaluation of Comfort With the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Xibrom (Bromfenac Ophthalmic Solution) 0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bp Consulting, Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bp Consulting, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate and compare the comfort of bromfenac or nepafenac
      following SLT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, single armed, cross over controlled study to evaluate comfort and IOP
      (Intraocular Pressure) changes of specific NSAIDs post SLT. Patients (n= 25, total 50 eyes)
      scheduled to undergo bilateral Selective Laser Trabeculoplasty (SLT) will instill bromfenac
      in the first eye to undergo SLT, and the contra lateral eye will receive nepafenac.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of study medication</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure changes</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xibrom (bromfenac)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nevanac (nepafenac)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xibrom</intervention_name>
    <description>Xibrom: two times a day for seven days in the first eye.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>bromfenac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nevanac</intervention_name>
    <description>Nevanac: three times a day for seven days in the second eye.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>nepafenac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years old, either gender or any race.

          -  Diagnosis of open-angle glaucoma or ocular hypertension requiring laser
             trabeculoplasty.

          -  Completion of written and informed consent/authorization prior to any study related
             procedures.

          -  Able to follow study protocol and likely to complete study schedule.

        Exclusion Criteria:

          -  Known sensitivity to NSAIDs.

          -  History of neovascular or ocular inflammatory disease.

          -  Current use of topical or systemic anti-inflammatory medications.

          -  Females of childbearing potential.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nate Kleinfeldt, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coburn-Kleinfeldt Eye Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coburn-Kleinfeldt Eye Clinic</name>
      <address>
        <city>3340 6 mile Rd Livonia</city>
        <state>Michigan</state>
        <zip>48152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>June 8, 2009</last_update_submitted>
  <last_update_submitted_qc>June 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Nate Kleinfeldt</name_title>
    <organization>Coburn-Kleinfeldt Eye Clinic</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
    <mesh_term>Bromfenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

